Drug intelligence / Profile preview

Calmagrip Forte

Development stage
Unknown
Lead developer
Pharmex Group
Modality
Small Molecules
Administration
Oral
01

Overview

Calmagrip Forte is an oral combination medication developed and marketed by Pharmex Group for the symptomatic relief of common cold and influenza symptoms. It contains three active ingredients: paracetamol (650 mg), which acts as an analgesic and antipyretic; caffeine (25 mg), which serves as a central nervous system stimulant and adjuvant to enhance paracetamol's effects; and chlorphenamine maleate (4 mg), an H1 antihistamine that alleviates allergic symptoms such as sneezing, tearing, and nasal congestion. The product is approved in Spain for treating fever, mild to moderate pain, and catarrhal processes associated with the common cold and flu.

Brand names
Calmagrip Forte
Other names
Paracetamol/Caffeine/Chlorphenamine 650mg/25mg/4mgparacetamol + caffeine + chlorphenamine
02

Targets

ADORA1 (Adenosine receptor A1 subtype)PGHS-1 (Prostaglandin G/H Synthase 1)HRH1 (Histamine H1 Receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on Calmagrip Forte.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calmagrip Forte.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call